Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study by Tuomilehto, J. et al.
  1/1
 
 
 
Does diagnosis of the metabolic syndrome detect further 
men at high risk of cardiovascular death beyond those 
identified by a conventional cardiovascular risk score?  
The DECODE Study 
 
The DECODE Study Group 
 
 
 
 
Short title: Metabolic syndrome and cardiovascular risk scores 
 
Abstract: 226 words 
Text: 3011 words 
 
38 references 
4 Tables 
1 Figure 
 
 
 
 
 
Correspondence to:  
 
Beverley Balkau 
INSERM U780-IFR69 
16 Avenue Paul Vaillant Couturier 
94807 Villejuif cedex 
Telephone: 00 33 1 45 59 51 61 
Fax: 00 33 1 47 26 94 54 
e-mail: balkau@vjf.inserm.fr 
in
se
rm
-0
01
25
97
8,
 v
er
sio
n 
1 
- 2
3 
Ja
n 
20
07
Author manuscript, published in "European Journal of Cardiovascular Prevention & Rehabilitation 14, 2 (2007) 192-9"
 DOI : 10.1097/01.hjr.0000230107.78524.da
  2/2
Abstract 
 
Background  It is not known whether the metabolic syndrome detects further individuals at 
high risk of cardiovascular (CVD) mortality, beyond those identified by a conventional 
cardiovascular risk score.  
Design A prospective study 
Methods 2790 non-diabetic men, aged 50-69 years from seven population-based European 
cohorts participating in the DECODE Study, were followed for CVD mortality over 10 years.  
Results  51% of the men had an estimated 10-year risk of fatal CVD under 5%, using the 
European SCORE project equation, and 22% of them had the metabolic syndrome, as 
defined by the National Cholesterol Education Program Adult Treatment Panel III. In the 
low risk men, the hazards ratio for fatal CVD, after adjusting for age and study centre, was 
2.71 (1.33-5.51) for men with the syndrome (p < 0.01) compared to men without the syndrome. 
A large waist circumference (> 102 cm) carried an odds ratio of 2.24 (1.05-4.76) in the low 
CVD risk men  
Conclusions Men with a low cardiovascular risk score and the metabolic syndrome had a 
significantly higher risk of fatal CVD than those without the syndrome. Use of the metabolic 
syndrome in clinical practice is thus justified in men, but the waist circumference provided a 
simpler diagnostic tool with similar fatal CVD risk in these low risk men. A large waist 
circumference could be used for pre-screening, and could be included in CVD risk scores. 
 
Key words: cardiovascular diseases, epidemiology, obesity, risk factors  
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Introduction 
Identification of the metabolic or insulin resistance syndrome is currently being recommended to 
identify people at risk for cardiovascular disease (CVD), and for diabetes [1-5]. Numerous studies 
have shown that both prevalent and incident diabetes and CVD are associated with the syndrome, as 
defined by the World Health Organization (WHO)[1], by the European Group for the study of 
Insulin Resistance (EGIR)[6], by the National Cholesterol Education Program, Adult Treatment 
Panel III (NCEP-ATP III)[2] or by adaptations of these definitions [7-24]. Further, in 2005 two 
additional definitions of the metabolic syndrome have been published, one by the International 
Diabetes Federation (IDF)[25], and a second, a revised version of the NECP-ATP III definition,  by 
the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) [26]. 
 
However, while the syndrome may predict diabetes, this is mainly due to those subjects with the 
syndrome who have high glucose concentrations (impaired glucose tolerance or impaired fasting 
glucose) at baseline [9,11,18,19,21,22]. A combination of other diabetes risk factors (glucose and 
insulin at both fasting and 2 hours post load, triglycerides, HDL-cholesterol, systolic and diastolic 
blood pressure, weight, height) has been shown to better predict diabetes than either the WHO or 
the NCEP-ATP III defined syndromes [16,19]. For cardiovascular mortality, there are many studies 
[7-17,22-24], and the syndrome is significantly predictive, even after adjusting for the traditional 
CVD risk factors (blood pressure, cholesterol, smoking as well as age) [10,11,13,15,17,23,24]. 
However, the Framingham Risk equation appears to have a better predictive value than the 
metabolic syndrome [16]. 
 
If the syndrome is to be a useful concept in clinical practice it should identify individuals at risk of 
CVD beyond those who can already be identified by a cardiovascular risk score. The European 
SCORE project risk equation [27] is appropriate for identifying those at low and high risk of fatal 
CVD (10-year risk under and over 5%) in European populations [28]. 
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In the DECODE cohort, we study whether the syndrome identified individuals who died within 10 
years of CVD among those a) at low CVD risk, b) at high CVD risk. Further we study in these two 
groups the predictive value of the syndrome abnormalities taken singly and as a combination of the 
two clinical variables, waist circumference and arterial blood pressure, and of the hyper-
triglyceridaemic waist, which has been proposed as a simple tool for the diagnosis of the 
syndrome [29]. 
 
Methods 
Study population 
The methods used to recruit cohorts into the DECODE Study have been reported in previous 
publications [14,30-32]. Briefly, coordinators of studies with data on mortality from population-
based studies or large studies on occupational groups in Europe, and with measured glucose 
concentrations at fasting and 2 hours after a 75g OGTT, were contacted and invited to participate. 
Data were collated and analyzed in the Diabetes and Genetic Epidemiology Unit of the National 
Public Health Institute in Helsinki, Finland.  
 
We analyze data from seven population-based studies from the DECODE study cohorts, 2790 men 
aged 50 to 69 years with measures of fasting glucose, triglycerides, HDL-cholesterol 
concentrations, waist circumference and systolic and diastolic blood pressures. There were too few 
cardiovascular events in this DECODE population with the syndrome variables to permit analysis 
outside this age range. Women were included in the DECODE cohort, but the number of CVD 
deaths was small, and so results have not been included in this report. Diabetic men, both known 
and screened (fasting plasma glucose ≥ 7.0 mmol/l) were excluded [1]. All glucose concentrations 
were transformed to plasma glucose concentrations, as already documented in other DECODE 
Study publications [14,30-32]. 
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Each study had ethical approval in accord with local requirements. 
 
Score Risk Equation for CVD risk stratification 
The probability of 10-year CVD mortality was calculated for all men in the study, using the 
formulae developed by the European SCORE project, summing the probabilities of CHD and CVD-
non-CHD deaths [27]. This score includes sex, age, smoking status, total cholesterol and systolic 
blood pressure. These risk equations do not take into account diabetes or glucose concentrations, 
nor obesity measures. The coefficients for ‘low risk countries’ were used for Spain, Italy, the 
Netherlands, and ‘high risk countries’ for Finland, Sweden, Poland and the UK. Men with a 10-year 
cardiovascular mortality risk under 5% were identified as being at ‘low risk’ and men with a risk 
over 5% as ‘high risk’, in line with the European guidelines [27]. 
 
The metabolic syndrome 
The NCEP-ATP III defined metabolic was used, modified to include treatment for hypertension [2]. 
This definition requires the presence of at least three of the following five abnormalities: 
hyperglycaemia: fasting plasma glucose > 6.1 mmol/l; high arterial blood pressure: systolic 
> 130 mmHg and/or diastolic > 85 mmHg or treatment for hypertension; hypertriglyceridaemia: 
triglycerides > 1.7 mmol/l; hypo-HDL cholesterolaemia: HDL-cholesterol < 1.04mmol/l; central 
adiposity: waist circumference > 102 cm. 
 
Vital status 
Vital status was followed for the men who attended the baseline examination. Those who 
emigrated, for whom vital status could not be confirmed, were censored at the time of emigration. 
Follow-up was almost complete. Fatal events were classified using the International Classification 
of Diseases: CVD was defined by codes 401-448 of the Eighth or Ninth Revisions and codes I10-
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I79 for the Tenth Revision [33,34]. Causes of death were either classified by an independent panel, 
or death certificates were used. 
 
Statistical Analyses 
SPSS for Windows 11.0 has been used for all statistical analyses.  
 
Men were divided into four groups according to < 5%/≥ 5% estimated CVD risk and 
absence/presence of the NCEP-ATP III metabolic syndrome. The mean values of risk factors and 
the ranges over the studies, are presented (Table 1).  
 
The Cox proportional hazards model was used to estimate the 10-year hazards ratios for fatal CVD, 
using men without the syndrome and at low CVD risk, as the reference group. The 10-year CVD 
cumulative hazards curves were calculated for these four risk groups. Because the syndrome and the 
CVD risk score include the same variables (arterial blood pressures), and age is included in the 
SCORE risk equation, models were build successively, with initially no adjustment, and then 
successive adjustment for centre, for centre and age and finally for centre, age and the estimated 
CVD risk from the SCORE equation [27]. The final adjustment for the estimated CVD risk aimed 
to examine whether the residual risk in the men with the syndrome was due to the traditional CVD 
risk factors or to other factors included in the syndrome, such as abdominal obesity, hyperglycemia 
and the specific lipid abnormalities.  
 
In order to examine the CVD mortality linked with the syndrome in the high CVD risk group, the 
hazards ratios were also determined separately, in the groups with low and high CVD risk scores. 
 
To determine which of the syndrome abnormalities was driving the CVD risk, hazards ratios for the 
individual syndrome abnormalities were estimated, within the two CVD risk groups, with the 
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abnormalities defined according to the NCEP-ATP III thresholds. Finally, the risk associated with 
the combination of the two clinically determined variables, large waist circumference and high 
arterial blood pressure was evaluated, and also the risk associated with the combination of high 
triglycerides and large waist circumference [29].  
 
Results 
The characteristics of the men, aged 50 to 69 years, included in this study are shown (Table 1). The 
follow-up in this analysis was limited to ten years. The most frequent abnormality contributing to 
the metabolic syndrome was high arterial blood pressure, with a frequency of 72% and the 
syndrome was present in 24% of the men. 
 
The SCORE CVD risk equation identified 51% of the men (n=1416) as having a risk of fatal CVD 
under 5% over the next 10 years (Table 2). Of these, 22% (n=306) had the metabolic syndrome.  
 
Overall 4.2% (n=118) of the men died of CVD,  2.2% (33/1416) of those at low CVD risk and 6.2% 
(85/1374) of those at high CVD risk.  In both the low and the high CVD risk groups, the mean 
values of all variables indicated a higher risk in those with the metabolic syndrome (Table 2). This 
was particularly true for the syndrome variables.  
 
The primary objective of this analysis was to determine, in men at low CVD risk, whether those 
with the metabolic syndrome had significantly higher CVD mortality than those without the 
syndrome. The hazards ratios changed little after adjustment, and even after adjusting for the 
estimated CVD risk, the metabolic syndrome remained predictive with a hazards ratio (95% 
confidence interval) of 2.42 (1.20-4.88) (p < 0.05) (Table 3). For the high CVD risk men, the 
hazards ratios were more affected by the adjustments: when adjusted for centre alone, the risks of 
fatal CVD were higher than for the low CVD risk men with the syndrome, but after adjustment for 
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age and centre, the hazards ratios were similar to the men with low CVD risk and the syndrome. 
Further, adjusting for the estimated 10-year CVD risk using the SCORE equation, the observed 
hazards ratio in the high risk men was greatly reduced, showing that the risk was due to high values 
of the classical CVD risk factors. Analyzing the two CVD risk groups separately, showed that the 
metabolic syndrome did not predict CVD mortality in the high risk men, with hazards ratios very 
close to one.  
 
The cumulative hazards for the four groups of men are shown in Figure 1, and illustrate the similar 
risks in men at high CVD risk, with and without the syndrome and in men at low CVD risk with the 
syndrome.  
 
Among the individual syndrome abnormalities, for the men in the low CVD risk group, large waist, 
high blood pressure, low HDL-cholesterol were predictive of fatal CVD with similar hazards ratios 
of 2.24 (1.05-4.76), 2.67 (1.21-5.88) and 2.72 (1.35-5.45) respectively (Table 4). The highest 
hazards ratio was associated with the combination of large waist and high arterial blood pressure, 
3.54 (1.65-7.59). These men were 13% of those at low CVD risk, a smaller target group for 
potential intervention than the 22% with the metabolic syndrome in this group.  
 
The individual metabolic syndrome variables were not predictive of 10 year CVD mortality in the 
high CVD risk men.  
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Discussion 
In men with a low risk of fatal CVD, as estimated by the SCORE project risk equations [27], 
presence of the metabolic syndrome at baseline increased the chances of fatal CVD over the 10-year 
follow-up, using the clinical definition of the metabolic syndrome given by the NCEP-ATP III [2]. 
This risk was related to syndrome abnormalities and not to the risk identified by the SCORE 
equation for CVD mortality, as the syndrome remained predictive after adjustment by the estimated 
CVD risk. The positive predictive values for fatal CVD in men using the waist circumference alone 
was 4.1% and for the metabolic syndrome 4.2%, with hazards ratios of  2.24 and 2.71 respectively; 
the waist criteria provides a simpler alternative to the syndrome as screening could be targeted 
towards a smaller fraction of the population, 17% versus 22% of the men at low CVD risk. The high 
blood pressure, large waist criteria had an associated hazards ratio of 3.54, a positive predictive 
value of 5.3% and screened 13% of the low risk population: these two variables are readily 
available in general practice. 
 
Limitations of the Study 
Our study is limited by the small number of cardiovascular deaths. In contrast to other studies, we 
have limited the analysis to subjects between 50 and 69 years, as there were too few men with an 
estimated risk of fatal CVD deaths over 5% before 50 years of age and too few subjects over 69 
years, thus there has been no extrapolation of the results to other age groups, based on few deaths in 
these age groups. Unfortunately we do not have access to cardiovascular morbidity in most of these 
DECODE populations. The CVD risk score developed for Europe is appropriate, but scores such as 
the Framingham risk equation should provide similar results, and would rank subjects similarly, 
although many of these score are for morbidity and not mortality. Of the men identified by the 
SCORE risk equation as being at high fatal CVD risk, 6.1% died of CVD, in contrast to the 
expected 5%. However, the SCORE equation is not country specific, and only stratifies according 
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to ‘high’ and ‘low’ risk countries. The data were also analyzed deleting the 44 men who were 
diabetic according to the 2-hour post-load glucose criteria. The hazards ratios were little altered.  
 
A further limitation is the use of the NCEP-ATP III criteria for the definition of the metabolic 
syndrome, which we have already discussed [35]. This definition was designed for clinical use, and 
our study was designed to provide practical answers. It was a consensus definition from an expert 
committee in the United States, where the blood pressure levels are lower than in Europe [36] and 
the waist circumferences are larger [35]. Using the thresholds of the NCEP-ATP III syndrome, we 
classified two thirds of our population as having high arterial blood pressure. In almost all 
populations, the waist circumference criteria of the NCEP-ATP III screen more women than men. 
These thresholds were not chosen on the basis of CVD mortality, and given the higher rate of CVD 
in men, waist circumference thresholds which screen more men than women would seem 
appropriate. With better adapted thresholds, the waist circumference might provide a very 
convenient first screening tool, without the need for taking a blood sample. The syndrome criteria 
are not optimal, and indeed it would be preferable to have a continuous metabolic score rather than 
a dichotomous classification [37]. 
 
We have chosen to study only the NCEP-ATP III syndrome [2], so that these results can be 
compared with other publications, most of which use this syndrome definition. This study is only of 
mortality as morbidity data were not available in all of the populations in this study. Further the 
follow-up is limited to 10 years. The metabolic syndrome may be a risk factor for a higher lifetime 
risk of cardiovascular consequences, and studying only mortality and for only 10 years, may limit 
findings on the utility of the metabolic syndrome. Altough Type 2 diabetes has been identified as a 
CVD risk equivalent to established CVD [2], we have studied only one outcome of the metabolic 
syndrome in these analyses, fatal CVD and not progression to diabetes, which in the long term 
would have CVD consequences, although not necessarily yet within a 10-year period. [38]. Using a 
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combined endpoint, diabetes and CVD events may have an important impact on the risk associated 
with the syndrome. Information on incident diabetes is not available in these populations. It should 
be noted, that these results are for European Caucasians aged 50 to 69 years, thus similar analyses 
are required in other populations and age groups to determine whether they can be generalized. 
 
Other Studies 
A previous analysis of the DECODE cohort [14] examined the risk associated with the metabolic 
syndrome, using adaptations of the WHO syndrome definition, and using various combinations of 
the abnormalities. Indeed, all syndrome definitions used were predictive of CVD mortality in men, 
in accord with our results. 
 
One published study analyzed major CVD events, stratifying subjects on the 10-year CVD risk 
(fatal and non-fatal events) estimated from the Framingham score, with high risk being a > 20% 
probability of an event [13]. Participants were from the placebo groups of two clinical trials (4S and 
AFCAPS/TexCAPS) on cholesterol lowering in high risk individuals, average age 58 years, and 
more than 75% were men. In men at low CVD risk, those with the syndrome had a higher 
cumulative incidence of a major coronary event than those without the syndrome, but this was not 
formally tested. In these two clinical trials, the metabolic syndrome conferred statistically 
significant age-adjusted hazards ratios of 1.5 and 1.4 for a major coronary event. In our study, the 
corresponding fatal CVD hazards ratio for the syndrome was higher in men at low CVD risk, 
being 2.7.  
 
Data from the population based San Antonio Study [16] show that while the metabolic syndrome 
had an odds ratio of almost 4 for CVD events, after adjustment by the Framingham CVD risk score, 
this risk was reduced to non-significant 1.14 (0.76-1.71). These data were not analyzed by sex, and 
could well be compatible with our results, where the metabolic syndrome was only found to be 
in
se
rm
-0
01
25
97
8,
 v
er
sio
n 
1 
- 2
3 
Ja
n 
20
07
  12/12
predictive in the low risk men. ROC curves show that the Framingham risk score has higher 
sensitivity/specificity for CVD events than the metabolic syndrome, but this is not surprising given 
that the Framingham score has been specifically developed to include variables that best predict 
CVD events, in contrast to the metabolic syndrome which is a combination of potential risk factors, 
published by an expert committee.  
 
In the ARIC cohort, more than 1000 incident events in men and women 45 to 64 years, over a 
follow-up of 11 years, were registered [17]. The metabolic syndrome was found to be predictive of 
CVD events, both in men and women, but as in the San Antonio Study, the metabolic syndrome did 
not improve the coronary risk prediction beyond the level achieved by the Framingham risk score.  
 
The Hoorn Study, a European cohort of middle aged men and women, adjusting for the 
Framingham category reduced the hazards ratio of fatal and non-fatal CVD events associated with 
the metabolic syndrome, to 1.64 (1.11-2.44) in men and 1.17 (0.73-1.87) in women [23]. 
 
Analyses need to be repeated in other studies with more subjects and so more CVD deaths and with 
an extended age range. The sensitivity of the results to the actual thresholds used in the metabolic 
syndrome definition should also be studied. 
 
Conclusions 
Our study has shown that the metabolic syndrome, as defined by NCEP-ATP III, is predictive of 
fatal cardiovascular disease, but only in the men with a low risk of fatal CVD. The syndrome 
provides no further predictive information in men at high CVD risk.  Of note is the predictive value 
of the waist circumference with similar odds ratios to the NCEP-ATP III syndrome in the low risk 
men. It is a simple screening tool and it could be included as a risk factor in CVD risk scores. 
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Legend to Figure: 
Cumulative hazards of 10 year cardiovascular mortality in non-diabetic men aged 50 to 69 years, 
stratified according to the estimated cardiovascular risk from the SCORE project equation  
(10 year fatal risk of CVD </> 5%) and absence/presence of the NCEP-ATP III metabolic syndrome.   
Note: the curves for the two groups of men with a high CVD risk score, with and without the syndrome,  
are superimposed, and that the scale for the hazards for women and men differ. The DECODE Study. 
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Table 1  Characteristics (numbers, % and means (SD)) of 2790 non-diabetic men aged 50 to 69 years,  
according to sex. The DECODE Study.  
  Mean or percentage 
Range  
across centres 
Maximum follow-up (years)  10.0 6.9 – 10 
(10 years in 73% of the men) 
Age (years) 50-69 50-64 to 50-69 
Smoking  
Waist (cm) 
32% 
95 
18% - 43% 
92 - 98 
      Waist > 102 cm 20% 13% – 31% 
Fasting plasma glucose (mmol/l) 5.53 5.23 – 5.85 
      Impaired fasting glucose  
          (fasting plasma glucose  
           6.1 – 6.9 mmol/l) 
19% 10% - 38% 
 
Triglyceride (mmol/l) 
1.65 1.42 – 1.82 
      Triglyceride ≥ 1.70 mmol/l 37% 27% - 43% 
Total cholesterol (mmol/l) 6.20 5.52 – 6.59 
HDL cholesterol (mmol/l) 1.25 1.18 – 1.40 
       HDL cholesterol < 1.04 mmol/l) 28% 11% - 35% 
Systolic Blood Pressure (mmHg) 139  133 - 148 
      SBP/DBP ≥ 130/85 mmHg  
         or treated for hypertension 
72% 61% - 87% 
   
NCEP-ATP III syndrome 26% 16% – 37% 
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Table 2  Characteristics (mean (SD)) of the non-diabetic men aged 50-69 years, according 
to the estimated cardiovascular risk from the SCORE project equation and 
absence/presence of the NCEP-ATP III metabolic syndrome. The DECODE Study. 
 CVD risk over 10 years from the SCORE project equation 
 < 5% > 5% 
 no syndrome syndrome no syndrome syndrome 
 20 deaths, 
1110 men 
13 deaths,  
306 men 
57 deaths,  
941 men 
28 deaths,  
433 men 
Age (years) 56 (5) 56 (4) 62 (5) 61 (5) 
Waist (cm) 92 (8) 102 (9) 93 (8) 103 (9) 
BMI (kg/m²) 25.6 (2.8) 29.0 (3.6) 25.8 (3.0) 29.1 (3.5) 
Systolic blood pressure (mmHg) 128 (15) 139 (14) 146 (21) 153 (18) 
Fasting glucose (mmol/l) 5.4 (0.5) 5.8 (0.6) 5.4 (0.5) 5.9 (0.6) 
Total cholesterol (mmol/l) 6.0 (1.1) 6.1 (1.1) 6.3 (1.1) 6.5 (1.2) 
HDL-cholesterol (mmol/l) 1.3 (0.3) 1.0 (0.2) 1.4 (0.3) 1.0 (0.2) 
Triglycerides (mmol/l) 1.3 (0.6) 2.4 (1.2) 1.4 (0.6) 2.5 (1.3) 
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Table 3 Hazards ratios (95% confidence intervals) of the 118 fatal cardiovascular events 
in 2790 non-diabetic men aged 50-69 year, according to the estimated cardiovascular risk 
from the SCORE project equation and absence/presence of the NCEP-ATP III metabolic 
syndrome. The DECODE Study.  
 CVD risk over 10 years from the SCORE project equation 
 < 5% > 5% 
 no syndrome with syndrome no syndrome with syndrome 
 20 deaths, 
1110 men 
13 deaths,  
306 men 
57 deaths,  
941 men 
28 deaths,  
433 men 
No adjustments    
 1  2.36 (1.17-4.74) 3.44 (2.06-5.73) 3.52 (1.98-6.27) 
Adjusting for centre 
 1  2.44 (1.21-4.91) 3.65 (2.16-6.16) 3.97 (2.20-7.17) 
Adjusting for centre, age 
 1 2.47 (1.22-4.99) 2.17 (1.20-3.93) 2.50 (1.31-4.74) 
Adjusting for centre, age and the estimated 10-year CVD risk  
 1 2.42 (1.20-4.88) 1.70 (0.91-3.17) 1.87 (0.95-3.68) 
Dividing men according to CVD risk group 
No adjustments    
 1 2.37 (1.17-4.76) 1 1.02 (0.65-1.62) 
Adjusting for centre 
 1 2.52 (1.24-5.09) 1 1.10 (0.69-1.74) 
Adjusting for centre and age 
 1 2.71 (1.33-5.51) 1 1.13 (0.71-1.80) 
Adjusting for centre, age and the estimated 10-year CVD risk  
 1 2.26 (1.09-4.68) 1 1.08 (0.68-1.72) 
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Table 4  Hazards ratios of the 118 fatal cardiovascular events in 2790 non-diabetic men 
aged 50-69 years, according to the estimated cardiovascular risk from the SCORE project 
equation and the NCEP-ATPIII defined abnormalities. Adjustment has been made for age 
and study centre. The DECODE Study. 
 CVD risk over 10 years from the SCORE project equation 
 < 5% > 5% 
     
WAIST WC < 102 cm WC ≥ 102 cm WC < 102 cm WC ≥ 102 cm 
 23 deaths,  
1174 men 
10 deaths,  
242 men 
67 deaths,  
1060 men 
18 deaths,  
314 men 
 1 2.24 (1.05-4.76) 1 0.93 (0.54-1.58) 
     
BLOOD 
PRESSURE 
SBP/DBP 
< 130/85  
SBP/DBP 
≥ 130/85 
SBP/DBP 
< 130/85 
SBP/DBP 
≥ 130/85 
 9 deaths,  
576 men 
24 deaths,  
840 men 
8 deaths,  
192 men 
77 deaths,  
1182 men 
 1 2.67 (1.21-5.88) 1 1.82 (0.86-3.83) 
     
FASTING 
GLUCOSE 
Glucose  
< 6.1 mmol/l  
Glucose  
≥ 6.1 mmol/l 
Glucose  
< 6.1 mmol/l 
Glucose  
≥ 6.1 mmol/l 
 25 deaths,  
1195 men 
8 deaths,  
221 men 
62 deaths,  
1056 men 
23 deaths,  
318 men 
 1 1.73 (0.76-3.91) 1 1.05 (0.99-1.11) 
     
HDL-
CHOLESTEROL 
HDL-C 
≥ 1.04 mmol/l  
HDL-C 
< 1.04 mmol/l 
HDL-C 
≥ 1.04 mmol/l 
HDL-C 
< 1.04 mmol/l 
 15 deaths,  
997 men 
18 deaths,  
419 men 
59 deaths,  
1020 men 
26 deaths,  
354 men 
 1 2.72 (1.35-5.45) 1 1.30 (0.81-2.09) 
 
TRIGLYCERIDE 
 
TRIG 
< 1.70 mmol/l  
TRIG 
≥ 1.70 mmol/l 
TRIG 
< 1.70 mmol/l 
TRIG 
≥ 1.70 mmol/l 
 21 deaths,  
940 men 
12 deaths,  
476 men 
53 deaths,  
824 men 
32 deaths,  
550 men 
 1 1.29 (0.63-2.65) 1 0.96 (0.61-1.50) 
     
BLOOD 
PRESSURE 
& WAIST 
SBP/DBP 
< 130/85  
&/or  
WC < 102 cm 
SBP/DBP 
≥ 130/85 
&  
WC ≥ 102 cm 
SBP/DBP 
< 130/85 
&/or  
WC < 102 cm 
SBP/DBP 
≥ 130/85 
&  
WC ≥ 102 cm 
 23 deaths,  
1229 men 
10 deaths,  
187 men 
68 deaths,  
1077 men 
17 deaths,  
297 men 
 1 3.54 (1.65-7.59) 1 0.93 (0.54-1.59) 
     
TRIGLYCERIDE 
& WAIST 
TRIG 
< 1.7 mmol/l 
&/or  
WC < 102 cm 
TRIG 
≥  1.7 mmol/l  
&  
WC ≥ 102 cm 
TRIG 
< 1.7 mmol/l  
&/or  
WC < 102 cm 
TRIG 
≥  1.7 mmol/l  
&  
WC ≥ 102 cm 
 29 deaths,  
1299 men 
4 deaths,  
117 men 
78 deaths,  
1205 men 
7 deaths,  
169 men 
 1 1.91 (0.66-5.54) 1 0.69 (0.31-1.51) 
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Cumulative  
hazards 
 
low CVD risk score, 
no syndrome 
low CVD risk score, 
syndrome
high CVD risk score, 
syndrome
curve coincident with
high CVD risk score, 
no syndrome
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